A study on NSCLC patients treated with anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) found that patients with a higher blood TMB (bTMB) had a shorter PFS and OS [102]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.